Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.

Chinese medical journal - 1 Jan 2011

Ren Guan-Jun, Zhao Yuan-Yuan, Zhu Yu-Jia, Xiao Yi, Xu Jia-Sen, Shan Bin, Zhang Li

Abstract excerpt

BACKGROUND: Molecular targeted drugs is now widely used in non-small cell lung cancer (NSCLC) clinical treatment. Icotinib hydrochloride is a new type of oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs). In this study, we examined the role of EGFR, K-RAS, B-RAF somatic mutations and EGFR mRNA expression in tumor specimens from advanced NSCLC patients as predicators of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crown Ethers

Share to ErbB Receptors

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to Quinazolines

Source

Identifiers

PMID: 21362302

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.PMID 21362302Read ↗

EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment.Semantic proximity Read ↗

Detection of EGFR somatic mutations in non-small cell lung cancer (NSCLC) using a novel mutant-enriched liquidchip (MEL) technology.Semantic proximity Read ↗

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.Semantic proximity Read ↗

[Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer].Semantic proximity Read ↗

An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting.Semantic proximity Read ↗

[Immunohistochemical detections of EGFR status in NSCLC].Semantic proximity Read ↗

A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.Semantic proximity Read ↗

Measurement of Serum EGFR mRNA Expression is a Reliable Predictor of Treatment Response and Survival Outcomes in Non- Small Cell Lung Cancer.Semantic proximity Read ↗

Icotinib: efficacy in different solid tumors and gene mutations.Semantic proximity Read ↗

Identifying EGFR mutations from SCLC patient plasma by mutant-enriched liquidchip technology.Semantic proximity Read ↗

Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor-tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

Efficacy and influence factors of icotinib hydrochloride in treating advanced non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.